Biotech Values

[DewDiligence]

RCUS -29% on Roche’s anti-TIGIT failure in NSCLC:

https://finance.yahoo.com/news/genentech-reports-interim-results-phase-051000141.html

Genentech…today announced results from its Phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) versus Tecentriq alone as an initial (first-line) treatment for people with PD-L1-high locally advanced or metastatic non-small cell lung cancer (NSCLC). The study did not meet its co-primary endpoint of progression-free survival. At this first analysis, the other co-primary endpoint of overall survival (OS) was immature, and the study will continue until the next planned analysis.

This is tiragolumab’s second phase-3; the first failure was announced in March (#msg-168382636).

RCUS is not a Roche partner, but rather a competitor in the anti-TIGIT arena who is aligned with GILD.